Antonio Rivero-Juarez1, Loreto Martinez-Dueñas2, Antonio Martinez-Peinado2, Angela Camacho2, Celia Cifuentes3, Ana Gordon2, Mario Frias2, Julian Torre-Cisneros2, Juan A Pineda3, Antonio Rivero4. 1. Hospital Universitario Reina Sofia de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain. Electronic address: arjvet@gmail.com. 2. Hospital Universitario Reina Sofia de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain. 3. Instituto de Biomedicina de Sevilla (IBiS)/Hospital Universitario de Valme, Seville, Spain. 4. Hospital Universitario Reina Sofia de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain. Electronic address: ariveror@gmail.com.
Abstract
BACKGROUND & AIMS: The seroprevalence of the hepatitis E virus (HEV) and its chronicity rate in the HIV-infected population has not been well established. As a result, the magnitude of this emerging disease in this population cannot be established. METHODS: Prospective study that included HIV-infected patients followed up between September 2012 and May 2013. All included patients were tested for anti-HEV IgG/IgM. In patients with confirmed anti-HEV IgG/IgM positivity, RT-PCR was performed. In patients where HEV RNA was amplified, a second RT-PCR assay was performed 6 months later to identify transient or chronic HEV infections. RESULTS: Eight hundred and ninety-four HIV-infected patients were enrolled in the study. Of these patients, 399 (44.6%) were monoinfected with HIV; 462 (51.6%) were co-infected with HIV/HCV; 12 (1.3%) were co-infected with HIV/HBV; and 21 (2.3%) were co-infected with HIV/HCV/HBV. In 88 patients, anti-HEV IgG/IgM was detected (seroprevalence: 9.8% [95% CI: 8.02%-11.9%]). In five patients (0.5%; 95% CI: 0.2%-1.2%), HEV RNA was detected; 5.7% (95% CI: 2.1%-12.1%) of the patients were anti-HEV IgG/IgM positive. None of these patients showed detectable HEV RNA six months later. CONCLUSION: HEV infection is frequent in HIV-infected patients but developing a chronic HEV infection may be considered an uncommon liver disease in this population.
BACKGROUND & AIMS: The seroprevalence of the hepatitis E virus (HEV) and its chronicity rate in the HIV-infected population has not been well established. As a result, the magnitude of this emerging disease in this population cannot be established. METHODS: Prospective study that included HIV-infectedpatients followed up between September 2012 and May 2013. All included patients were tested for anti-HEV IgG/IgM. In patients with confirmed anti-HEV IgG/IgM positivity, RT-PCR was performed. In patients where HEV RNA was amplified, a second RT-PCR assay was performed 6 months later to identify transient or chronic HEV infections. RESULTS: Eight hundred and ninety-four HIV-infectedpatients were enrolled in the study. Of these patients, 399 (44.6%) were monoinfected with HIV; 462 (51.6%) were co-infected with HIV/HCV; 12 (1.3%) were co-infected with HIV/HBV; and 21 (2.3%) were co-infected with HIV/HCV/HBV. In 88 patients, anti-HEV IgG/IgM was detected (seroprevalence: 9.8% [95% CI: 8.02%-11.9%]). In five patients (0.5%; 95% CI: 0.2%-1.2%), HEV RNA was detected; 5.7% (95% CI: 2.1%-12.1%) of the patients were anti-HEV IgG/IgM positive. None of these patients showed detectable HEV RNA six months later. CONCLUSION:HEV infection is frequent in HIV-infectedpatients but developing a chronic HEV infection may be considered an uncommon liver disease in this population.
Authors: Pilar Clemente-Casares; Carlota Ramos-Romero; Eugenio Ramirez-Gonzalez; Antonio Mas Journal: Biomed Res Int Date: 2016-12-14 Impact factor: 3.411
Authors: Sonia Vázquez-Morón; Juan Berenguer; Juan González-García; Ma Ángeles Jiménez-Sousa; Isabel Canorea; Josep M Guardiola; Manuel Crespo; Carmen Quereda; José Sanz; Ana Carrero; Victor Hontañón; Ana Avellón; Salvador Resino Journal: Sci Rep Date: 2019-02-04 Impact factor: 4.379
Authors: Antonio Rivero-Juarez; María A Risalde; Mario Frias; Ignacio García-Bocanegra; Pedro Lopez-Lopez; David Cano-Terriza; Angela Camacho; Saul Jimenez-Ruiz; Jose C Gomez-Villamandos; Antonio Rivero Journal: BMC Vet Res Date: 2018-02-27 Impact factor: 2.741
Authors: Pedro López-López; Antonio Rivero-Juarez; Mario Frias; Isabel Machuca; Javier Caballero-Gómez; Israel Olivas; Angela Camacho; María de Los Angeles Risalde; Ignacio García-Bocanegra; Antonio Rivero Journal: Front Microbiol Date: 2019-11-07 Impact factor: 5.640